Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Clinical Trials

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Phase 4

Recruiting

Conditions: Portal Hypertension
Hepatic Decompensation
Advanced Chronic Liver Disease

Interventions: Drug: Carvedilol

First Posted Date: 2024-06-10

Last Posted Date: 2024-08-27

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 474

Registration Number: NCT06449339

Locations: 🇭🇰
Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

Not Applicable

Not yet recruiting

Conditions: Decompensated Cirrhosis
Cirrhotic Cardiomyopathy
Cirrhosis, Liver
Left Ventricular Diastolic Dysfunction
Acute Kidney Injury

Interventions: Drug: Simvastatin 20mg
Drug: Carvedilol 3.125 mg

First Posted Date: 2024-05-29

Last Posted Date: 2024-08-01

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 260

Registration Number: NCT06431919

Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy

Phase 1

Not yet recruiting

Conditions: Chemotherapy Induced Systolic Dysfunction

Interventions: Drug: Placebo
Drug: Carvedilol
Drug: Colchicine
Drug: Ramipril
Drug: Rosuvastatin

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Arab Contractors Medical Centre

Target Recruit Count: 150

Registration Number: NCT06304896

Locations: 🇪🇬
Arab Contractors Medical Centre, Cairo, Egypt

Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis

Early Phase 1

Not yet recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Carvedilol

First Posted Date: 2023-10-31

Last Posted Date: 2024-04-16

Lead Sponsor: Tanta University

Target Recruit Count: 70

Registration Number: NCT06108518

Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation

Not Applicable

Not yet recruiting

Conditions: Liver Cirrhosis

Interventions: Drug: Carvedilol
Drug: Pentoxifylline

First Posted Date: 2023-09-18

Last Posted Date: 2023-10-03

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 180

Registration Number: NCT06041932

Locations: 🇮🇳
Institute of Liver & Biliary Sciences., New Delhi, Delhi, India

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Phase 4

Not yet recruiting

Conditions: Cardiovascular Diseases
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Nebivolol
Drug: Valsartan and Sacubitril
Drug: Carvedilol
Drug: Bisoprolol
Drug: Metoprolol
Drug: Spironolactone

First Posted Date: 2023-09-13

Last Posted Date: 2024-01-18

Lead Sponsor: University Hospital Ostrava

Target Recruit Count: 100

Registration Number: NCT06035978

Locations: 🇨🇿
University Hospital Ostrava, Ostrava, Czech Republic, Czechia

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Phase 3

Recruiting

Conditions: End-Stage Renal Disease
End-Stage Kidney Disease

Interventions: Drug: Metoprolol Succinate
Drug: Carvedilol

First Posted Date: 2023-07-05

Last Posted Date: 2025-04-10

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 2540

Registration Number: NCT05931276

Locations: 🇺🇸
Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States
🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸
VA NY Harbor Healthcare System, New York, NY, New York, New York, United States